Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.
Megaro G, Miele E, Spinelli GP, Alessi I, Del Baldo G, Cozza R, Russo I, De Pasquale MD, Cefalo MG, Tomà P, Carai A, Di Ruscio V, De Ioris MA, Mastronuzzi A.
Megaro G, et al. Among authors: mastronuzzi a.
Cancer Rep (Hoboken). 2022 Mar;5(3):e1483. doi: 10.1002/cnr2.1483. Epub 2022 Jan 28.
Cancer Rep (Hoboken). 2022.
PMID: 35092185
Free PMC article.